Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Suppression of carrageenan-induced hyperalgesia, hyperthermia and edema by a bradykinin antagonist.

Literature DB >> 2482813

Suppression of carrageenan-induced hyperalgesia, hyperthermia and edema by a bradykinin antagonist.

Abstract

Although bradykinin (BK) antagonists have antinociceptive effects, they have not been evaluated for anti-inflammatory activity. When administered with carrageenan into the rat hindpaw, NPC567 significantly blocked carrageenan-induced hyperalgesia, hyperthermia and edema. In addition, NPC567 did not alter the in vitro release of immunoreactive BK by plasma kallikrein. These results indicate that the antinociceptive activity of NPC567, a BK antagonist, may be related to its overall anti-inflammatory activity and that is mechanism of action does not include inhibition of plasma kallikrein.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 1989 PMID： 2482813 DOI： 10.1016/0014-2999(89)90118-0

Source DB: PubMed Journal: Eur J Pharmacol ISSN： 0014-2999 Impact factor: 4.432

Keyword Cloud
Cited

15 in total

Review 1. Visceral perception: inflammatory and non-inflammatory mediators.

Authors: L Bueno; J Fioramonti
Journal: Gut Date: 2002-07 Impact factor: 23.059

2. Inhibition of rat paw oedema and pleurisy by the extract from Mandevilla velutina.

Authors: M G Henriques; P D Fernandes; V B Weg; R A Yunes; R S Cordeiro; J B Calixto
Journal: Agents Actions Date: 1991-07

3. Bradyzide, a potent non-peptide B(2) bradykinin receptor antagonist with long-lasting oral activity in animal models of inflammatory hyperalgesia.

Authors: G M Burgess; M N Perkins; H P Rang; E A Campbell; M C Brown; P McIntyre; L Urban; E K Dziadulewicz; T J Ritchie; A Hallett; C R Snell; R Wrigglesworth; W Lee; C Davis; S B Phagoo; A J Davis; E Phillips; G S Drake; G A Hughes; A Dunstan; G C Bloomfield
Journal: Br J Pharmacol Date: 2000-01 Impact factor: 8.739

4. Endogenous prolactin generated during peripheral inflammation contributes to thermal hyperalgesia.

Authors: Phoebe E Scotland; Mayur Patil; Sergei Belugin; Michael A Henry; Vincent Goffin; Kenneth M Hargreaves; Armen N Akopian
Journal: Eur J Neurosci Date: 2011-07-21 Impact factor: 3.386

5. Bradykinin initiates cytokine-mediated inflammatory hyperalgesia.

Authors: S H Ferreira; B B Lorenzetti; S Poole
Journal: Br J Pharmacol Date: 1993-11 Impact factor: 8.739

6. Bradykinin-induced activation of nociceptors: receptor and mechanistic studies on the neonatal rat spinal cord-tail preparation in vitro.

Authors: A Dray; I A Patel; M N Perkins; A Rueff
Journal: Br J Pharmacol Date: 1992-12 Impact factor: 8.739

Suppression of carrageenan-induced hyperalgesia, hyperthermia and edema by a bradykinin antagonist.

Review 1. Visceral perception: inflammatory and non-inflammatory mediators.

2. Inhibition of rat paw oedema and pleurisy by the extract from Mandevilla velutina.

3. Bradyzide, a potent non-peptide B(2) bradykinin receptor antagonist with long-lasting oral activity in animal models of inflammatory hyperalgesia.

4. Endogenous prolactin generated during peripheral inflammation contributes to thermal hyperalgesia.

5. Bradykinin initiates cytokine-mediated inflammatory hyperalgesia.

6. Bradykinin-induced activation of nociceptors: receptor and mechanistic studies on the neonatal rat spinal cord-tail preparation in vitro.

7. Local L-NG-monomethyl-arginine attenuates the vasodilator action of bradykinin in the human forearm.

8. Endothelin-1 inhibits PAF-induced paw oedema and pleurisy in the mouse.

9. Hoe 140 a new potent and long acting bradykinin-antagonist: in vitro studies.

10. Hoe 140 a new potent and long acting bradykinin-antagonist: in vivo studies.